Logo image of LXEO

LEXEO THERAPEUTICS INC (LXEO) Stock Price, Quote, News and Overview

NASDAQ:LXEO - Nasdaq - US52886X1072 - Common Stock - Currency: USD

2.649  -0.17 (-6.06%)

LXEO Quote, Performance and Key Statistics

LEXEO THERAPEUTICS INC

NASDAQ:LXEO (5/27/2025, 1:57:50 PM)

2.649

-0.17 (-6.06%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High19.5
52 Week Low1.45
Market Cap87.95M
Shares33.20M
Float31.79M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO11-03 2023-11-03


LXEO short term performance overview.The bars show the price performance of LXEO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

LXEO long term performance overview.The bars show the price performance of LXEO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of LXEO is 2.649 USD. In the past month the price decreased by -23.37%. In the past year, price decreased by -81.76%.

LEXEO THERAPEUTICS INC / LXEO Daily stock chart

LXEO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.07 327.86B
AMGN AMGEN INC 13.41 149.74B
GILD GILEAD SCIENCES INC 14.05 135.30B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.21B
REGN REGENERON PHARMACEUTICALS 13.69 65.48B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 38.29B
ARGX ARGENX SE - ADR 99.33 35.60B
ONC BEIGENE LTD-ADR 6.07 25.67B
BNTX BIONTECH SE-ADR N/A 23.80B
NTRA NATERA INC N/A 21.54B
SMMT SUMMIT THERAPEUTICS INC N/A 19.49B
BIIB BIOGEN INC 8.17 18.95B

About LXEO

Company Profile

LXEO logo image Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The company is headquartered in New York City, New York and currently employs 72 full-time employees. The company went IPO on 2023-11-03. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Company Info

LEXEO THERAPEUTICS INC

345 Park Avenue South, Floor 6

New York City NEW YORK US

Employees: 69

LXEO Company Website

Phone: 12125479879

LEXEO THERAPEUTICS INC / LXEO FAQ

What is the stock price of LEXEO THERAPEUTICS INC today?

The current stock price of LXEO is 2.649 USD. The price decreased by -6.06% in the last trading session.


What is the ticker symbol for LEXEO THERAPEUTICS INC stock?

The exchange symbol of LEXEO THERAPEUTICS INC is LXEO and it is listed on the Nasdaq exchange.


On which exchange is LXEO stock listed?

LXEO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for LEXEO THERAPEUTICS INC stock?

13 analysts have analysed LXEO and the average price target is 21.57 USD. This implies a price increase of 714.11% is expected in the next year compared to the current price of 2.649. Check the LEXEO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is LEXEO THERAPEUTICS INC worth?

LEXEO THERAPEUTICS INC (LXEO) has a market capitalization of 87.95M USD. This makes LXEO a Micro Cap stock.


How many employees does LEXEO THERAPEUTICS INC have?

LEXEO THERAPEUTICS INC (LXEO) currently has 69 employees.


What are the support and resistance levels for LEXEO THERAPEUTICS INC (LXEO) stock?

LEXEO THERAPEUTICS INC (LXEO) has a support level at 2.62 and a resistance level at 3.26. Check the full technical report for a detailed analysis of LXEO support and resistance levels.


Should I buy LEXEO THERAPEUTICS INC (LXEO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does LEXEO THERAPEUTICS INC (LXEO) stock pay dividends?

LXEO does not pay a dividend.


What is the Price/Earnings (PE) ratio of LEXEO THERAPEUTICS INC (LXEO)?

LEXEO THERAPEUTICS INC (LXEO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.3).


What is the Short Interest ratio of LEXEO THERAPEUTICS INC (LXEO) stock?

The outstanding short interest for LEXEO THERAPEUTICS INC (LXEO) is 10.33% of its float. Check the ownership tab for more information on the LXEO short interest.


LXEO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

LXEO Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to LXEO. While LXEO seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LXEO Financial Highlights

Over the last trailing twelve months LXEO reported a non-GAAP Earnings per Share(EPS) of -3.3. The EPS decreased by -22.18% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -86.97%
ROE -124.05%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%-28.57%
Sales Q2Q%N/A
EPS 1Y (TTM)-22.18%
Revenue 1Y (TTM)-100%

LXEO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to LXEO. The Buy consensus is the average rating of analysts ratings from 13 analysts.


Ownership
Inst Owners103.17%
Ins Owners1.35%
Short Float %10.33%
Short Ratio3.15
Analysts
Analysts86.15
Price Target21.57 (714.27%)
EPS Next Y22.84%
Revenue Next YearN/A